智通财经5月30日电，华音国际控股在港交所公告，将于今天下午一时起短暂停止买卖。 ...

华音国际控股(00989.HK)：将于今天下午一时起短暂停止买卖。 ...

根据智通财经APP了解，公司2023年营收断崖式下滑主要是由于甘氨酸及三氯蔗糖的平均售价下降。 营收细化来看，于往绩记录期间，三氯蔗糖销售额分别占各期总收益约49.6%、51.1%及41.8%，食品级甘氨酸销售额分 别占总收益约40.6%、40.1%及42.0%，以及工业级甘氨酸销售额分别占总收益约7.6%、6.1%及11.7%。 2023年食品级甘氨酸平均售价从上年的3.28万元每吨降至1.7万元，2024年维持在1.78万元的低位。三氯蔗糖平均售价则 从31.17万元降至23.68万元，再降至18.48万元。这导致公司毛利率从25.6%降至17%左右，净利率则从16%降至7.6%。 在全球健康饮食的浪潮下，代糖市场迎来爆发式增长。截至2024年，全球代糖产品市场规模达221亿美元，我国代糖产 品市场规模亦突破100亿元规模。 行业增长之时，代糖巨头新琪安于5月28日通过港交所聆讯。作为全球食品级甘氨酸龙头、三氯蔗糖第五大制造商，新 琪安难掩业绩剧烈波动、客户高度集中的经营风险。登陆资本市场之后，投资者能否为新琪安的代糖龙头故事买单 吗？ 业绩深陷失速困局 招股书显示，按2023年销量及销售收益计，新琪安在 ...

基石投资方面，新琪安以与Reynold Lemkins及合赢订立基石投资协议，基石投资者同意认购约6000万港元的发售股份。 新琪安2003年成立，专注于食品添加剂的生产与销售。主要产品有高倍甜味剂三氯蔗糖，食品级、工业级甘氨酸，是全球领先的食品配料生产商。按2023 年销量及销售收益计，新琪安于全球食品级甘氨酸制造行业排名第一；就食品级甘氨酸而言，按2023年销量及销售收益计，公司的全球市占率分别约为 5.1%及3.1%。 2022年至2024年期间，新琪安有大约150名来自各行各业的客户。于2024年，公司三氯蔗糖、食品级甘氨酸以及工业级甘氨酸销售额分别占总收益约 41.8%、42.0%及11.7%。 近两年，新琪安经营业绩表现不佳，2022年至2024年，收入由7.61亿元(单位人民币，下同)下降至5.69亿元，年内溢利由1.22亿元下降至4340.6万元。 2024年，新琪安来自欧洲及北美市场的收入占比超过60%，其中北美市场(业务覆盖美国及加拿大)的收入增长迅猛。 | | | | 截至12月31日止年度 | | | | | --- | --- | --- | --- | --- | --- | -- ...

Core Viewpoint - MINISO's recent financial report reveals a trend of revenue growth but profit decline, raising concerns among investors about its future performance and market position [1][5][6]. Financial Performance - In Q1 2025, MINISO achieved revenue of 4.427 billion yuan, a year-on-year increase of 18.9%, with a gross profit of 1.958 billion yuan, up 21.1% [6][8]. - The net profit for the same period was 417 million yuan, down 28.8% from 586 million yuan in the previous year, leading to a net profit margin decrease of 3.3% to 13.3% [8][9]. - The decline in profit is attributed to a shift in revenue structure, with lower-margin direct sales increasing relative to higher-margin franchise and agency businesses [8][9]. Market Expansion and Strategy - As of March 31, 2025, MINISO had a total of 7,768 stores, with a net increase of 978 stores year-on-year, including 4,275 in China and 3,213 overseas [9][10]. - The company is focusing on closing underperforming small stores while opening larger ones, with an average new store size of nearly 300 square meters [10][13]. - MINISO's overseas revenue grew by 30.3%, contributing to a 3% increase in total revenue share from international markets [6][9]. IP Strategy and Challenges - The company has been heavily investing in external IP acquisitions, with IP-related expenses reaching 421 million yuan in 2024, a nearly 30% increase year-on-year [14][15]. - Despite the high costs, MINISO continues to launch over 10,000 new IP products annually, but faces challenges in maintaining product exclusivity and differentiation in a competitive market [14][15]. Future Outlook - MINISO plans to spin off its rapidly growing toy brand TOP TOY for a potential IPO, aiming to raise approximately 300 million USD [15][16]. - The company is also set to consolidate its operations with Yonghui Supermarket, which may increase short-term profitability pressures due to ongoing restructuring efforts [18][22]. - CEO Ye Guofu remains optimistic about future performance, emphasizing refined operational strategies and enhanced IP collaborations [23].

Core Viewpoint - The Chinese liquor industry is entering a deep adjustment period in 2024, with intensified market competition and frequent personnel changes, prompting companies to view "reform" as a key driver for exploring new growth points to meet challenges and seize opportunities [2]. Company Overview - Huaren Beer Chairman Hou Xiaohai has reduced his shareholding in the company twice in May, cashing out over 26 million HKD, which has sparked market speculation [4][6]. - Hou Xiaohai has been with Huaren Beer for 24 years and previously led the company to become the top-selling beer brand in China with the "Brave the World" strategy [4][7]. - The company has invested over 10 billion CNY in acquiring several liquor companies, including Jingzhi Liquor, Jinzongzi Liquor, and Jinsha Liquor, positioning Hou as a key player in the liquor sector [4][10]. Strategic Developments - In the final year of the "3+3+3" strategy, Hou Xiaohai aims for liquor revenue to exceed 10 billion CNY and profits to reach 2 billion CNY, indicating a need for substantial breakthroughs in the "beer and liquor dual empowerment" strategy [5][14]. - The "3+3+3" strategy has led to significant improvements in Huaren Beer’s financials, with gross profit margin rising from 33.71% to 42.36% and revenue increasing from 28.694 billion CNY to 38.635 billion CNY from 2016 to 2024 [8]. Liquor Business Performance - The liquor business currently has a scale of over 4 billion CNY, with a target to exceed 10 billion CNY in the future [17]. - In 2024, the liquor business generated revenue of 2.149 billion CNY, with a slight increase in EBITDA to 807 million CNY [12]. - The other two acquired companies, Jinzongzi and Jingzhi, have faced challenges, with Jinzongzi's revenue declining by 37.04% to 925 million CNY and continuing losses [13]. Future Outlook - The company aims to leverage its capital advantages and nationwide channel capabilities to enhance brand structure and expand nationally, focusing on market promotion and product pricing control [19]. - Experts believe that achieving the 10 billion CNY revenue target will require optimizing product structures and increasing the proportion of mid-to-high-end products [20].

以"一波三折"来形容重塑能源(02570)上市以来的股价表现最为贴切不过。 于2024年12月6日成功在香港上市后，重塑能源股价在横盘半个月后便开始趋势性上涨，4个月的时间内，其股价最高涨至316.2港元每股，这较147港元的发 行价累涨115.1%，实现了股价的翻倍式上涨。 但在随后的仅仅13个交易日内，重塑能源股价便从316.2港元跌至最低点的118港元，跌幅高达62.68%，这较公司发行价亦下跌近20%，高位后的调整可谓是 相当猛烈，直接砸穿了发行价。 而在触及118港元的历史低位之后，重塑能源股价于当日再次开启趋势性上涨，不到2个月的时间最高涨至267.4港元，最大涨幅高达115.19%。 而在自5月26日以来的四个交易日，重塑能源股价累跌超近20%，直接跌破10日均线趋势。不过，重塑能源股价需面对的挑战可不止于此，智通财经APP观 察到，重塑能源在IPO时引进的基石投资者所持有的股份将于6月6日迎来解禁，这或将让其近期股价表现承压。若基石解禁后选择兑现盈利，或将对重塑能 源的股价造成更为明显的影响。 实际流通筹码仅约3% 重塑能源股价的"大起大落"其实与大盘的起伏高度重合，将重塑能源股价与恒生指数对 ...

Group 1 - Rongda Technology (容大科技) is launching an IPO, planning to issue 18.4 million shares globally, with 16.56 million shares for international offering and 1.84 million shares for public offering in Hong Kong [1] - The indicative price range for the shares is between HKD 10.00 and HKD 12.00, with an estimated net proceeds of HKD 148.3 million if priced at HKD 11.00 and without the exercise of the over-allotment option [1] - The public offering in Hong Kong will start on May 30, 2025, and end on June 5, 2025, with the final price and allocation results to be announced on June 9, 2025 [1] Group 2 - Rongda Technology is a global supplier of Automatic Identification and Data Capture (AIDC) devices and solutions, involved in the design, research, manufacturing, and marketing of printing devices, scales, POS terminals, and PDAs [2] - The AIDC devices are used for automatic identification of objects, data collection, and data transmission to systems, widely applied across various industries [3] Group 3 - From fiscal year 2022 to 2024, Rongda Technology's revenue was RMB 393 million, RMB 349 million, and RMB 350 million, with net profits of RMB 37.4 million, RMB 27.6 million, and RMB 41.3 million respectively [4] - As of the end of 2024, the company's cash and cash equivalents were only RMB 7.6 million [4] - The company's shares are relatively concentrated, with major shareholders expected to hold approximately 74.98% of the issued share capital after the global offering [4] - Prior to the IPO, the company distributed dividends of RMB 5 million, RMB 35 million, and RMB 31.5 million to shareholders for the fiscal years 2022 to 2024 [4]

29日，省人民医院富阳院区正式试运行，特别为百姓开设了专家义诊。义诊云集了50余位省人民医 院知名专家，涵盖内科、外科、妇科、儿科等多个学科，义诊号上线即"秒空"。义诊期间，医院还推出 了中医药文化体验区，开展了健康宣教与主题讲座。据悉，当天共有千余名群众参与了义诊及相关活 动。 值得一提的是，富阳院区通过"门诊—医技—病房"的集中式功能布局，使整体诊疗流程更便捷简 短，给患者带来全程一站式贴心服务。 徐继介绍，试运行阶段，富阳院区门诊全部开放，急诊开放内科、外科、儿科、耳鼻喉科，住院开 放三个病区（内科综合病区、外科综合病区、急诊综合病区）；预计7月底前逐步实现全面启用，启用 进度将第一时间向社会公布。此外，富阳院区从试运行起6个月内，所有专家门诊、名医门诊均免除专 家挂号费部分，按普通门诊挂号标准收费。 富阳院区位于富阳区春江街道竹简路300号，占地184.5亩，按三级甲等综合医院标准建设，设置总 床位数1800张。一期设置床位1200张，共有机动车车位1683个。 目前，富阳院区依托省人民医院优质医疗资源，开设临床科室45个、医技科室10个，主要特色专科 包括头颈外科、泌尿外科、乳腺外科、血管外科等。 ...

港股众安在线(06060.HK)跌超10%，成交额超16亿港元。 ...